Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer.

Authors :: Loupakis, Fotios
Cremolini, Chiara
Masi, Gianluca
Lonardi, Sara
Zagonel, Vittorina
Salvatore, Lisa
Cortesi, Enrico
Tomasello, Gianluca
Ronzoni, Monica
Spadi, Rosella
Zaniboni, Alberto
Tonini, Giuseppe
Buonadonna, Angela
Amoroso, Domenico
Chiara, Silvana
Carlomagno, Chiara
Boni, Corrado
Allegrini, Giacomo
Boni, Luca
Falcone, Alfredo
Source :: New England Journal of Medicine. 10/23/2014, Vol. 371 Issue 17, p1609-1618. 10p. 1 Diagram, 3 Charts, 2 Graphs.
Publication Year :: 2014
Abstract: The article presents a study that reveals the promise offered by chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab in treating metastatic colorectal cancer as compared with fluorouracil, leucovorin, and irinotecan (FOLFIRI). The study involved 12 cycles of treatment followed by fluorouracil plus bevacizumab until disease progression and show improved outcome in patients with metastatic colorectal cancer in FOLFOXIRI plus bevacizumab.

Subjects :: *COLON cancer treatment
*ANTINEOPLASTIC agents
*FLUOROURACIL
*BEVACIZUMAB
*CANCER invasiveness

Full Text Access

Tools